PCVX vs. EXEL, CRSP, HALO, RVMD, KRYS, QGEN, IMVT, RGEN, IOVA, and TECH
Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), Krystal Biotech (KRYS), Qiagen (QGEN), Immunovant (IMVT), Repligen (RGEN), Iovance Biotherapeutics (IOVA), and Bio-Techne (TECH). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends.
Exelixis currently has a consensus price target of $26.29, suggesting a potential upside of 10.17%. Vaxcyte has a consensus price target of $78.50, suggesting a potential upside of 14.60%. Given Exelixis' stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Exelixis.
Exelixis has a net margin of 11.35% compared to Exelixis' net margin of 0.00%. Vaxcyte's return on equity of 8.57% beat Exelixis' return on equity.
Exelixis received 543 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 68.13% of users gave Exelixis an outperform vote while only 66.67% of users gave Vaxcyte an outperform vote.
Exelixis has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 2.9% of Exelixis shares are held by company insiders. Comparatively, 3.6% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Exelixis has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exelixis had 1 more articles in the media than Vaxcyte. MarketBeat recorded 7 mentions for Exelixis and 6 mentions for Vaxcyte. Exelixis' average media sentiment score of 0.74 beat Vaxcyte's score of 0.64 indicating that Vaxcyte is being referred to more favorably in the news media.
Summary
Exelixis beats Vaxcyte on 11 of the 17 factors compared between the two stocks.
Get Vaxcyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools